[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-neuropathy-peripheral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-neuropathy-peripheral":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100602378","additional-effects-of-proprioceptive-neuromuscular-facilitation-with-otago-exercises-on-fall-risk-in-diabetes-mellitus-patients-100602378",false,"NCT07122726","Additional Effects of Proprioceptive Neuromuscular Facilitation With Otago Exercises on Fall Risk in Diabetes Mellitus Patients","Inclusion Criteria:\n\n* Diabetes type 2 patients\n* 50-75 years of age\n* Both Males and Female Gender\n* Duration of diabetes more than 5 years\n* Participants positive for Michigan Neuropathy Screening Instrument\n* Patients having berg balance scale score \\>20\n\nExclusion Criteria:\n\n* Surgical procedure involving knee, ankle, or hip joints.\n* Foot Ulcers and Deformities.\n* Diagnosis of neurological diseases (CVA, MS, Parkinson disease etc.) besides DPN.\n* Absence of Visual Impairment and Hearing loss Patients having comprehension difficulties\n* Physical disability that prevents from performing the exercises","ALL","50 Years","75 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Diabetes Mellitus is considered as one of the most prevalent issues among global population and 50% of all the diabetic patients particularly diabetes type II develop peripheral neuropathy. Diabetic Peripheral Neuropathy (DPN) affects feet and legs first, followed by the hands and arms.\n\nThis study will involve two groups, one performing the Otago Exercise Program, and the other performing a combined PNF and Otago exercise protocol. This study aims to assess the additional effects of Proprioceptive Neuromuscular Facilitation with Otago Exercise Program on Risk of fall which will be assessed by assessing balance, Fear of Fall and Sensory Function.\n\nKey outcome measures, including the Berg Balance Scale, Fall Efficacy Scale, Functional Reach test and Semmes Weinstein Monofilament Test will be used in evaluating the effectiveness of the exercise interventions. The participants would be screened through Michigan Neuropathy Screening Instrument and Berg Balance scale for inclusion criteria, and outcome measures will be assessed by using Berg Balance Scale, Fall efficacy scale, Functional Reach Test and Semmes Weinstein Monofilament testing method on the day of starting the intervention and on the last day of intervention. Intervention will be given for a total of 40-50 minutes per session, 3 sessions\u002Fweek for consecutive 6 weeks And than the data will be recorded at the end of 6 weeks again.",[26,27,28,29,30,31,32],"Postural Balance","Fall Risk","Diabetes (DM)","Fear of Falling","Sensory Function","Diabetic Neuropathy Peripheral","Proprioceptive Neuromuscular Facilitation",[34,35,36,37,38,39,40,41],"Balance","Fall risk","Fear of fall","sensory function","Otago Exercises","Proprioceptive neuromuscular facilitation","Diabetic Peripheral Neuropathy","Diabetes Mellitus","RECRUITING","2025-08-07",{"date":45,"type":46},"2025-08-14","ACTUAL",{"date":48,"type":46},"2024-09-13",{"date":50,"type":20},"2026-01-10",{"name":52,"class":53},"Foundation University Islamabad","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100531577","phase-2-evaluating-a-nitric-oxide-generator-nebivolol-as-a-disease-modifier-in-patients-with-diabetic-neuropathy-100531577","NCT06201611","Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.","A 3-arm, Open-label, Stratified Randomized Controlled Trial With Blinded End-point Assessment to EValuate A Nitric oxidE Generator (Nebivolol) as a diSease Modifying mediCatioN in Diabetic Peripheral Neuropathy","EVANESCENT-DPN","Inclusion Criteria:\n\n1. Patients aged \\>= 18 years diagnosed with diabetes mellitus, of a duration of \\\u003C= 5 years since their diagnosis\n2. HbA1c \\\u003C 9 at enrolment with stable glycemic control for the last three months\n3. Neuropathy meeting the following 'Toronto criteria' (8) - (a) abnormal nerve conduction study\\* based on age-matched controls at the site and - (b) a symptom or sign of neuropathy defined as one of either a diabetic neuropathy symptom score of \\>= 1\u002F4 Or neuropathy disability score of \\>= 3\u002F10 (9).\n\n   * Abnormal NCS defined as one or more abnormal Z score in two or more nerves, based on sural nerve amplitude (antidromic stimulation), tibial and peroneal NCV, tibial amplitude, increased F-wave minimum latency (F-min), and absent F-waves (only considered abnormal in tibial nerve)\n\nExclusion Criteria:\n\n1. Absolute contra-indications for nebivolol - sick-sinus syndrome, sinus bradycardia with a resting heart rate \\\u003C 50\u002F minute, second or third degree AV-nodal blocks fascicular blocks, severe asthma or COPD and acute heart failure\n2. Patients with a compelling indication for a non-dihydropyridine calcium channel blocker (CCB)\n3. Patients with compelling need for another beta-blocker in the judgement of the treating team\n\nPatients who have undergone major amputations of the lower limbs or are posted for the same.","18 Years",{"count":65,"type":20},120,[67,68],"PHASE2","PHASE3","The goal of this clinical trial is to test in patients with diabetic neuropathy,\n\n* Can Nevibolol at a dose of 2.5 mg- 10 mg compared with standard pain modulating treatment conserve the mean nerve action potential amplitude (sural and tibial nerves) at 24 weeks follow- up.\n* Can Nevibolol at a dose of 2.5 mg- 10 mg compared with a combination of Alpha Lipoic Acid (600 mg\u002Fday)+EPALRESTAT (150 mg\u002Fday) conserve the mean nerve action potential amplitude (sural and tibial nerves) at 24 weeks follow- up\n\n  * All potential participants will undergo screening- about 10 ml of blood will be drawn to perform the following assesments at screening- HbA1c, FBS,Vit B12, TSH, fT4.\n  * Baseline assessments conducting a nerve conduction study, quality of life assesment using Eq-5D-5L and NRS pain score.\n  * 20% of patients (24 patients) will undergo Sudoscan, Corneal confocal microscopy and a skin biopsy for assessing IENFD (Intra Epidermal Nerve Fibre Density).\n  * 15th day, 1 month and 3rd month followup for evaluating patients status and medication adherance.\n  * 6th month followup for evaluating patients status and medication adherance.\n\nResearchers will compare Nebivolol against combination of Epalrestat+Alpha Lipoic Acid against standard pain modulating treatment to evaluate their diseaes modifying effect as reflected by nerve conduction study parameters.",[31],"2025-02-01",{"date":73,"type":46},"2025-02-04",{"date":75,"type":46},"2024-11-15",{"date":77,"type":20},"2026-03-30",{"name":79,"class":53},"St. John's Research Institute",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":15,"minAge":63,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100474697","determining-patterns-in-trial-experiences-of-diabetic-neuropathy-patients-100474697","NCT05461274","Determining Patterns In Trial Experiences of Diabetic Neuropathy Patients","An In Depth Study Examining Patterns in the Clinical Trial Experiences of Diabetic Neuropathy Patients","Inclusion Criteria:\n\n* Patient plans to participate in an interventional clinical trial for the condition of diabetic neuropathy\n* Patient has been diagnosed with a type of diabetic neuropathy\n* Patient is a minimum of 18 years of age\n* Patient has access to a home internet connection in order to provide regular updates through the course of the study\n\nExclusion Criteria:\n\n* Patient is not able to provide consistent digital updates as per study requirements\n* Patient does not complete or agree to terms outlined in the Informed Consent Form\n* Patient has an ECOG score of 4 or higher",{"count":89,"type":20},500,"OBSERVATIONAL","Historically, participation in clinical studies is highly skewed towards particular demographic groups of people.\n\nThis study will invite several participants to gather a wide range of information on clinical trial experiences for diabetic neuropathy patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of diabetic neuropathy.\n\nThe data collected from this study will help improve future outcomes for all diabetic neuropathy patients as well as those in under-represented demographic groups.",[93,31],"Diabetic Neuropathies",[95,96],"diabetic neuropathy","neuropathy","NOT_YET_RECRUITING","2023-12-29",{"date":100,"type":46},"2024-01-02",{"date":102,"type":20},"2024-08",{"date":104,"type":20},"2026-08",{"name":106,"class":107},"Power Life Sciences Inc.","INDUSTRY"]